Lack of awareness and knowledge is resulted in poor uptake of the HIV prevention drug
Stigma, as well as lack of awareness and knowledge is resulted in poor uptake of the HIV prevention drug - the pre-exposure prophylaxis. Commonly known as PrEP, the drug has so far been initiated to about 300-thousand people globally. Most users are in North America, accounting for 71 per cent. Meanwhile, Sub-Saharan Africa, a region heavily burdened by the HIV epidemic holds 15 per cent of the total global PrEP initiation. These results were revealed at the HIV Research for Prevention Conference underway in the Spanish Capital, Madrid. Channel Africa's Jane Rabothata spoke to Laura Fitch of the AIDS Vaccine Advocacy Coalition…..